New Research Shows Dual Therapy Upon Diagnosis of MIS-C Improves Cardiac Outcomes
Photo: Pixabay/CC0 Public Domain
A recent study by a multidisciplinary team of cardiologists and infectious disease specialists at Children’s Hospital Colorado (Children’s Colorado) found that pediatric patients suffering from Multisystem Inflammatory Syndrome (MIS-C) who received initial, intensified therapy consisting of intravenous immunoglobulin (IVIG) plus Infliximab had improved cardiac outcomes versus those who received IVIG alone. In addition, those patients had a decreased need for additional therapies, decreased length-of-stay in the ICU, decreased development of left ventricular dysfunction, and more rapid resolution of inflammation. Infliximab is a medication often used to treat autoimmune diseases.
As a ...